CBC Group, a healthcare-dedicated asset management firm headquartered in Singapore, has completed the strategic acquisition of global biopharmaceutical company UCB’s mature neurology and allergy business in China, in partnership with Mubadala Investment Company.
 
The acquisition marks another successful transaction under CBC’s buyout strategy of acquiring key assets from global pharmaceutical companies and a significant step in establishing a market-leading neurology company in China while expanding CBC’s portfolio within the region’s dynamic pharmaceutical market. The transaction, valued at $680 million, includes UCB’s brands Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and the Zhuhai manufacturing site.
 
The medicine portfolio will serve as an anchor asset as CBC works to build out a leading integrated central nervous system (CNS) biopharma platform in China. Beyond strengthening CBC’s presence in the Chinese healthcare market, the acquisition also enhances the firm’s capabilities in meeting the rising demand for neurology and allergy treatments in the wider region. In collaboration with Mubadala, CBC will tap into its proprietary investor-operator approach, healthcare expertise and platform synergies to drive operational efficiencies, innovation and scale to benefit more patients across the region.
 
Fu Wei, CEO of CBC Group, said, “There is clear potential within the regional healthcare space to better serve patients with unmet medical needs in this growing CNS therapeutics market, and we are delighted to partner with Mubadala once again. This acquisition complements our existing healthcare ecosystem and aligns with our robust buyout strategy, which is strategically positioned to drive long-term, sustainable value in today’s healthcare investing market. Together, we are making a profound impact on the industry by harnessing our combined expertise and capital to not only enhance patient outcomes but also build value for our stakeholders. Leveraging our joint strengths, we are poised to capitalize on synergies and deploy hands-on strategic guidance to make significant strides in CNS market access and innovation.”
 
Named “NeuroGen Pharma,” the new company embodies what CBC and Mubadala envision for neuro healthcare innovation. The company will be led by an experienced management team with an extensive track record in the biopharma industry, ensuring a smooth transition to propel it into the next phase of growth.
 
NeuroGen Pharma is expected to deliver quality treatments to a wider reach of patients and play an important role in addressing the evolving neurology treatment needs in China. The company aims to leverage innovative therapies and cutting-edge research to enhance patient outcomes and shape the future of neurology care in the region.

Other Pharma Industry Acquisitions